Verastem Inc VSTM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer
Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology to Participate in Upcoming November Investor Conferences
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $6.86
- Day Range
- $6.25–6.82
- 52-Week Range
- $3.43–10.82
- Bid/Ask
- $6.32 / $6.90
- Shares Outstanding
- 126.01M
- Market Cap
- $797.67M
- Volume/Avg
- 3M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 102
- Website
- https://www.verastem.com
Valuation
Metric | VSTM |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 59.20 |
Price/Sales | 6.06 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | VSTM |
|---|---|
Quick Ratio | 1.77 |
Current Ratio | 1.93 |
Interest Coverage | −132.11 |
Quick Ratio
VSTM
Profitability
Metric | VSTM |
|---|---|
Return on Assets (Normalized) | −85.22% |
Return on Equity (Normalized) | −504.81% |
Return on Invested Capital (Normalized) | −142.33% |
Return on Assets
VSTM
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Xd$^f# | LOCK|QgH?X | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|>Y#d<>% | LOCK|H%^% | $95B | |||
| Moderna Inc MRNA | LOCK|>RMJ#g | LOCK|t% | $79B | |||
| argenx SE ADR ARGX | LOCK|s!V&BZ | LOCK|!< | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$&%Q%z | LOCK|h$ | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|%X!s&<&^ | LOCK|QST&^ | $30B | |||
| Incyte Corp INCY | LOCK|^^<KLT | LOCK|y> | $23B | |||
| BioNTech SE ADR BNTX | LOCK|r!#Hr> | LOCK|QBb | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|x&d>SW | LOCK|&gs!> | $19B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|qGq?lR# | LOCK|M^C | $15B |